Incyte Corporation

INCY

$9.90B

Mid Cap

NASDAQServices-Commercial Physical & Biological Researchpharmaceuticals🇺🇸North AmericaWILMINGTON2.6K employees

Incyte Corporation is an American multinational pharmaceutical company with headquarters in Wilmington, Delaware. The company currently operates manufacturing and R&D locations in North America, Europe, and Asia.

Website

Drugs in Pipeline

Phase 3 Programs

Upcoming Catalysts

Next Catalyst

Feb 25, 2026

17d

Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply

Market Overview

Stock performance and market intelligence

Catalyst Timeline

29 upcoming, 4 past

⭐Phase 3Next

Povorcitinib Phase 3 Results Expected

Feb 25, 2026Povorcitinib467

Primary completion for Povorcitinib trial (NCT06113445) in NonSegmental Vitiligo

Source

⭐Phase 3

Povorcitinib Phase 3 Results Expected

Mar 17, 2026Povorcitinib450

Primary completion for Povorcitinib trial (NCT06113471) in NonSegmental Vitiligo

Source

⭐Phase 3

Lenalidomide Phase 3 Results Expected

Apr 1, 2026Lenalidomide82

Primary completion for Lenalidomide trial (NCT05429268) in Large B-Cell Lymphoma

Source

⭐Phase 3

Tafasitamab Phase 3 Results Expected

Apr 1, 2026Tafasitamab82

Primary completion for Tafasitamab trial (NCT05429268) in Large B-Cell Lymphoma

Source

Phase 2

pemigatinib Phase 2 Results Expected

Apr 14, 2026Pemigatinib206

Primary completion for pemigatinib trial (NCT04463771) in Endometrial Cancer

Source

Phase 2

retifanlimab Phase 2 Results Expected

Apr 14, 2026Retifanlimab206

Primary completion for retifanlimab trial (NCT04463771) in Endometrial Cancer

Source

Phase 2

INCAGN02385 Phase 2 Results Expected

Apr 14, 2026INCAGN02385206

Primary completion for INCAGN02385 trial (NCT04463771) in Endometrial Cancer

Source

Phase 2

epacadostat Phase 2 Results Expected

Apr 14, 2026Epacadostat206

Primary completion for epacadostat trial (NCT04463771) in Endometrial Cancer

Source

Phase 2

INCAGN02390 Phase 2 Results Expected

Apr 14, 2026INCAGN02390206

Primary completion for INCAGN02390 trial (NCT04463771) in Endometrial Cancer

Source

Phase 2

povorcitinib Phase 2 Results Expected

Jun 15, 2026Povorcitinib240

Primary completion for povorcitinib trial (NCT05851443) in Moderate to Severe Asthma

Source

Phase 2

ICS-LABA Phase 2 Results Expected

Jun 15, 2026ICS-LABA240

Primary completion for ICS-LABA trial (NCT05851443) in Moderate to Severe Asthma

Source

Phase 2

itacitinib Phase 2 Results Expected

Jun 22, 2026Itacitinib18

Primary completion for itacitinib trial (NCT04640025) in Myelofibrosis

Source

Phase 2

INCA034176 Phase 2 Results Expected

Jul 3, 2026INCA03417630

Primary completion for INCA034176 trial (NCT06843408) in Chronic Graft-versus-host-disease

Source

⭐Phase 3

Ruxolitinib Phase 3 Results Expected

Jul 13, 2026Ruxolitinib240

Primary completion for Ruxolitinib trial (NCT06832618) in Atopic Dermatitis

Source

Phase 2

INCB099280 Phase 2 Results Expected

Jul 22, 2026INCB09928073

Primary completion for INCB099280 trial (NCT05879822) in Advanced Solid Tumor

Source

⭐Phase 3

Vehicle Cream Phase 3 Results Expected

Aug 10, 2026Vehicle Cream180

Primary completion for Vehicle Cream trial (NCT06548360) in NonSegmental Vitiligo

Source

⭐Phase 3

Ruxolitinib Cream Phase 3 Results Expected

Aug 10, 2026Ruxolitinib Cream180

Primary completion for Ruxolitinib Cream trial (NCT06548360) in NonSegmental Vitiligo

Source

⭐Phase 3

Tafasitamab Phase 3 Results Expected

Sep 1, 2026Tafasitamab899

Primary completion for Tafasitamab trial (NCT04824092) in Diffuse Large B-cell Lymphoma

Source

⭐Phase 3

Prednisone Phase 3 Results Expected

Sep 1, 2026Prednisone899

Primary completion for Prednisone trial (NCT04824092) in Diffuse Large B-cell Lymphoma

Source

⭐Phase 3

Cyclophosphamide Phase 3 Results Expected

Sep 1, 2026Cyclophosphamide899

Primary completion for Cyclophosphamide trial (NCT04824092) in Diffuse Large B-cell Lymphoma

Source

⭐Phase 3

Lenalidomide Phase 3 Results Expected

Sep 1, 2026Lenalidomide899

Primary completion for Lenalidomide trial (NCT04824092) in Diffuse Large B-cell Lymphoma

Source

⭐Phase 3

Vehicle Cream Phase 3 Results Expected

Oct 9, 2026Vehicle Cream450

Primary completion for Vehicle Cream trial (NCT06959225) in Hidradenitis Suppurativa

Source

⭐Phase 3

Ruxolitinib Cream Phase 3 Results Expected

Oct 9, 2026Ruxolitinib Cream450

Primary completion for Ruxolitinib Cream trial (NCT06959225) in Hidradenitis Suppurativa

Source

⭐Phase 3

Povorcitinib Phase 3 Results Expected

Oct 19, 2026Povorcitinib330

Primary completion for Povorcitinib trial (NCT06516965) in Prurigo Nodularis

Source

⭐Phase 3

Povorcitinib Phase 3 Results Expected

Dec 26, 2026Povorcitinib960

Primary completion for Povorcitinib trial (NCT06212999) in Hidradenitis Suppurativa (HS)

Source

Phase 2

tafasitamab Phase 2 Results Expected

Dec 31, 2026Tafasitamab72

Primary completion for tafasitamab trial (NCT04661007) in Non Hodgkins Lymphoma

Source

Phase 2

parsaclisib Phase 2 Results Expected

Dec 31, 2026Parsaclisib72

Primary completion for parsaclisib trial (NCT04661007) in Non Hodgkins Lymphoma

Source

Phase 2

R-CHOP Phase 2 Results Expected

Dec 31, 2026R-CHOP72

Primary completion for R-CHOP trial (NCT04661007) in Non Hodgkins Lymphoma

Source

Phase 2

lenalidomide Phase 2 Results Expected

Dec 31, 2026Lenalidomide72

Primary completion for lenalidomide trial (NCT04661007) in Non Hodgkins Lymphoma

Source

AI Predictions & Institutional Flow

Machine learning insights and smart money movement

FDA Submissions

Pending NDA/BLA submissions with predicted PDUFA dates

Drug Pipeline

Clinical development programs and drug candidates

Drug Pipeline

Sunitinib

Phase 3

Renal Cell Carcinoma (RCC)

Vehicle Cream

Phase 3

Prurigo Nodularis

Vehicle

Phase 3

Non-segmental Vitiligo

Lenalidomide

Phase 3

Large B-Cell Lymphoma

rituximab

Phase 3

Follicular Lymphoma

Epacadostat

Phase 3

Lung Cancer

Ruxolitinib

Phase 3

MPN (Myeloproliferative Neoplasms)

ruxolitinib tablets

Phase 3

Polycythemia Vera

Cyclophosphamide

Phase 3

Diffuse Large B-cell Lymphoma

Tacrolimus (Tac)

Phase 3

Graft-versus-host Disease (GVHD)

carboplatin

Phase 3

Squamous Cell Carcinoma of the Anal Canal

pembrolizumab + epacadostat

Phase 3

Melanoma

ibrutinib

Phase 3

Lymphoma

Pemetrexed

Phase 3

Metastatic Squamous Non-Small Cell Lung Cancer

Prednisone

Phase 3

Graft-versus-host Disease (GVHD)

Corticosteroids

Phase 3

Chronic Graft-versus-host-disease

Extracorporeal photopheresis (ECP)

Phase 3

Graft-versus-host Disease (GVHD)

Ruxolitinib Cream

Phase 3

Nonsegmental Vitiligo With Genital Involvement

Hydroxyurea (HU)

Phase 3

Polycythemia Vera

Povorcitinib

Phase 3

NonSegmental Vitiligo

Retifanlimab

Phase 3

Metastatic Merkel Cell Carcinoma

Tafasitamab

Phase 3

Diffuse Large B Cell Lymphoma

Bendamustine (BEN)

Phase 3

Diffuse Large B-cell Lymphoma

INCB123667

Phase 3

Ovarian Cancer

Investigator's choice of chemotherapy

Phase 3

Ovarian Cancer

Pembrolizumab

Phase 3

Head and Neck Cancer

Itacitinib

Phase 3

MPN (Myeloproliferative Neoplasms)

INCA034176

Phase 3

Chronic Graft-versus-host-disease

Capecitabine

Phase 2

Pancreatic Cancer

parsaclisib + itacitinib

Phase 2

B-Cell Malignancies

Oxaliplatin

Phase 2

Solid Tumor

MEDI4736

Phase 2

Solid Tumors

Ruxolitinib 1.5% cream

Phase 2

Vitiligo

Regorafenib

Phase 2

Pancreatic Cancer

Osimertinib

Phase 2

Lung Cancer

MK-3475

Phase 2

Microsatellite-instability (MSI) High Colorectal Cancer (CRC)

INCA000585

Phase 2

Immune Thrombocytopenia

INCAGN01876

Phase 2

Advanced Malignancies

INCAGN01949

Phase 2

Advanced Malignancies

R-CHOP

Phase 2

Non Hodgkins Lymphoma

INCB001158

Phase 2

Biliary Tract Cancer (BTC)

INCB177054

Phase 2

Solid Tumors

ICS-LABA

Phase 2

Moderate to Severe Asthma

Pemigatinib

Phase 2

Non-Small Cell Lung Cancer (NSCLC)

Ruxolitinib 25 mg

Phase 2

Multiple Myeloma

Nivolumab

Phase 2

B-cell Malignancies

Asparaginase Erwinia Chrysanthemi

Phase 2

Leukemia

INCB013739

Phase 2

Type 2 Diabetes

INCB000928

Phase 2

Anemia

Ruxolitinib phosphate cream

Phase 2

Psoriasis

INCB054707

Phase 2

Hidradenitis Suppurativa

Parsaclisib

Phase 2

B-Cell Malignancies

Ponatinib

Phase 2

Philadelphia Positive

Ruxolitinib 0.15% Cream QD

Phase 2

Atopic Dermatitis

INCB009471

Phase 2

HIV Infections

INCB099280

Phase 2

Advanced Solid Tumor

INCAGN02385

Phase 2

Endometrial Cancer

Axatilimab

Phase 2

Chronic Graft-versus-host-disease

INCAGN02390

Phase 2

Melanoma

Best available Treatment (BAT)

Phase 2

Chronic Graft-versus-host-disease

Gemcitabine

Phase 2

Solid Tumors

INCB018424

Phase 2

Rheumatoid Arthritis

INCB028050

Phase 2

Rheumatoid Arthritis

Prednisone or methylprednisolone

Phase 2

Graft-versus-host Disease (GVHD)

Ruxolitinib Phosphate

Phase 2

Psoriasis

Immune effector cell therapy

Phase 2

Cytokine Release Syndrome

Platinum-based chemotherapy

Phase 2

Lung Cancer

Drug Name	Phase	Indication	Designations
Sunitinib	Phase 3	Renal Cell Carcinoma (RCC)	-
Vehicle Cream	Phase 3	Prurigo Nodularis	-
Vehicle	Phase 3	Non-segmental Vitiligo	-
Lenalidomide	Phase 3	Large B-Cell Lymphoma	-
rituximab	Phase 3	Follicular Lymphoma	-
Epacadostat	Phase 3	Lung Cancer	-
Ruxolitinib	Phase 3	MPN (Myeloproliferative Neoplasms)	-
ruxolitinib tablets	Phase 3	Polycythemia Vera	-
Cyclophosphamide	Phase 3	Diffuse Large B-cell Lymphoma	-
Tacrolimus (Tac)	Phase 3	Graft-versus-host Disease (GVHD)	-
carboplatin	Phase 3	Squamous Cell Carcinoma of the Anal Canal	-
pembrolizumab + epacadostat	Phase 3	Melanoma	-
ibrutinib	Phase 3	Lymphoma	-
Pemetrexed	Phase 3	Metastatic Squamous Non-Small Cell Lung Cancer	-
Prednisone	Phase 3	Graft-versus-host Disease (GVHD)	-
Corticosteroids	Phase 3	Chronic Graft-versus-host-disease	-
Extracorporeal photopheresis (ECP)	Phase 3	Graft-versus-host Disease (GVHD)	-
Ruxolitinib Cream	Phase 3	Nonsegmental Vitiligo With Genital Involvement	-
Hydroxyurea (HU)	Phase 3	Polycythemia Vera	-
Povorcitinib	Phase 3	NonSegmental Vitiligo	-
Retifanlimab	Phase 3	Metastatic Merkel Cell Carcinoma	-
Tafasitamab	Phase 3	Diffuse Large B Cell Lymphoma	-
Bendamustine (BEN)	Phase 3	Diffuse Large B-cell Lymphoma	-
INCB123667	Phase 3	Ovarian Cancer	-
Investigator's choice of chemotherapy	Phase 3	Ovarian Cancer	-
Pembrolizumab	Phase 3	Head and Neck Cancer	-
Itacitinib	Phase 3	MPN (Myeloproliferative Neoplasms)	-
INCA034176	Phase 3	Chronic Graft-versus-host-disease	-
Capecitabine	Phase 2	Pancreatic Cancer	-
parsaclisib + itacitinib	Phase 2	B-Cell Malignancies	-
Oxaliplatin	Phase 2	Solid Tumor	-
MEDI4736	Phase 2	Solid Tumors	-
Ruxolitinib 1.5% cream	Phase 2	Vitiligo	-
Regorafenib	Phase 2	Pancreatic Cancer	-
Osimertinib	Phase 2	Lung Cancer	-
MK-3475	Phase 2	Microsatellite-instability (MSI) High Colorectal Cancer (CRC)	-
INCA000585	Phase 2	Immune Thrombocytopenia	-
INCAGN01876	Phase 2	Advanced Malignancies	-
INCAGN01949	Phase 2	Advanced Malignancies	-
R-CHOP	Phase 2	Non Hodgkins Lymphoma	-
INCB001158	Phase 2	Biliary Tract Cancer (BTC)	-
INCB177054	Phase 2	Solid Tumors	-
ICS-LABA	Phase 2	Moderate to Severe Asthma	-
Pemigatinib	Phase 2	Non-Small Cell Lung Cancer (NSCLC)	-
Ruxolitinib 25 mg	Phase 2	Multiple Myeloma	-
Nivolumab	Phase 2	B-cell Malignancies	-
Asparaginase Erwinia Chrysanthemi	Phase 2	Leukemia	-
INCB013739	Phase 2	Type 2 Diabetes	-
INCB000928	Phase 2	Anemia	-
Ruxolitinib phosphate cream	Phase 2	Psoriasis	-
INCB054707	Phase 2	Hidradenitis Suppurativa	-
Parsaclisib	Phase 2	B-Cell Malignancies	-
Ponatinib	Phase 2	Philadelphia Positive	-
Ruxolitinib 0.15% Cream QD	Phase 2	Atopic Dermatitis	-
INCB009471	Phase 2	HIV Infections	-
INCB099280	Phase 2	Advanced Solid Tumor	-
INCAGN02385	Phase 2	Endometrial Cancer	-
Axatilimab	Phase 2	Chronic Graft-versus-host-disease	-
INCAGN02390	Phase 2	Melanoma	-
Best available Treatment (BAT)	Phase 2	Chronic Graft-versus-host-disease	-
Gemcitabine	Phase 2	Solid Tumors	-
INCB018424	Phase 2	Rheumatoid Arthritis	-
INCB028050	Phase 2	Rheumatoid Arthritis	-
Prednisone or methylprednisolone	Phase 2	Graft-versus-host Disease (GVHD)	-
Ruxolitinib Phosphate	Phase 2	Psoriasis	-
Immune effector cell therapy	Phase 2	Cytokine Release Syndrome	-
Platinum-based chemotherapy	Phase 2	Lung Cancer	-

Regulatory & News

Approvals, filings, and latest developments

Regulatory Approvals

INCY News